Introduction

Methods Objective
To describe and report, by indication, patient distribution, key clinical effectiveness outcomes and safety data in children with growth hormone deficiency (GHD), born small for gestational age (SGA) or with Turner syndrome (TS), chronic renal disease (CRD), idiopathic short stature (ISS), Noonan syndrome (NS) or Prader-Willi syndrome (PWS) enrolled in the NordiNet ® International Outcome Study (IOS).
• Norditropin ® (somatropin; Novo Nordisk A/S, Denmark) is indicated in many countries for the treatment of short stature in paediatric patients with GHD, born SGA or TS, with additional indications of CRD, ISS, NS or PWS in a few select countries.
• The collection of real-world data is considered important to evaluate and characterise real-life effectiveness and safety in a large patient population over a long follow-up period.
• NordiNet ® IOS was a non-interventional study (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) 
Results
• The design and methodology of NordiNet ® IOS have been published previously. 1 • Patient information was entered using a web-based system. In total, 17,995 paediatric patients were enrolled: -17,711 included in the full analysis set (FAS: all patients exposed to growth hormone [GH] therapy that was initiated before age 18 years; used for safety evaluation). -11,967 included in the effectiveness analysis set (EAS: patients <18 years who were GH-naïve at baseline visit, and had valid baseline height, age and dosing information).
• Patients with a syndrome with co-existing GHD were classified by the syndrome. If they were both born SGA and had GHD, they were classified as GHD.
• Effectiveness outcomes included: -Change from baseline in height standard deviation score (ΔHSDS).
-Proportion (%) of patients with HSDS >−2.
-Near-adult height standard deviation score (NAH SDS) (NAH: height at age >16 years [boys]/>15 years [girls] and height velocity <2 cm/year or height at >18 years).
• Safety events were reported as serious adverse reactions (SARs) and nonserious adverse reactions (NSARs). Serious adverse events (SAEs) judged unrelated to GH therapy were also reported.
-Adverse reactions (NSARs/SARs) were classified by double causality assessment: if either the reporter or Novo Nordisk considered the relationship between a safety event and GH treatment as possible or probable, the event was classified as an adverse reaction.
Patient disposition
• The demographics and characteristics of GH-naïve paediatric patients, by indication, are shown in Table 1 .
• At treatment initiation: -Patients with PWS were the youngest (mean 4.7 years), followed by patients born SGA (mean 7.9 years), compared with the other indications (range: mean 8.3-10.1 years). 
Effectiveness
• For every indication, the ΔHSDS from baseline increased with treatment duration, with the greatest yearly gains achieved in year 1 (Figure 1 ).
-For TS, ΔHSDS was lower at 10 years than at 5 years. However, only a smaller subset of patients had 10 years of treatment, limiting the ability to draw definitive conclusions.
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• For every indication (with the exception of ISS), the proportion of patients with HSDS >−2 increased annually during GH treatment, until 3 years of treatment (Figure 2 ).
• NAH SDS are reported for GHD, SGA and TS (for other indications, only a small number of patients achieved NAH during the observation period). 
Safety
• For each indication, the safety profile was consistent with data in the approved labelling for Norditropin ® .
• No new safety signals were observed.
-Overall, a total 421 adverse reactions were reported: 288 NSARs in 249 patients; 133 SARs in 90 patients. In addition, there were 352 SAEs not related to GH therapy in 224 patients.
• There were 11 deaths among paediatric patients: four with GHD, one with SGA, two with CRD, one with PWS and three with other/unspecified diagnoses.
-Of these deaths, nine were considered unlikely to be related to GH treatment. -The deaths of two patients, following events assessed by the reporters as possibly related to GH treatment, are briefly described below: -A 16-year-old male in the GHD group, treated with GH from Sep 2003 to Aug 2011 (age at GH treatment start: 7.7 years). Medical history included: suprasellar cyst, hydrocephalus, short stature, congenital neurocutaneous melanosis and known hydrocephalus. In Aug 2011, he was increasingly tired, shaky and complained about abdominal pain; GH treatment was withdrawn. In Aug 2012 (1 year after the last GH injection), the patient was diagnosed with leptomeningeal melanocytosis and neurological symptoms due to leptomeningeal tumour. The patient died in May 2013. -A 20-year-old male, treated with GH due to GHD and CRD from Apr 2006 to an unknown date (age at GH treatment start age: 11.2 years). Medical history included: panhypopituitarism due to empty sella syndrome (since Jun 2006), GHD (since Apr 2006), perinatal asphyxia, CRD (since Jan 1995) with peritoneal dialysis (from Apr 2012) and epilepsy. In Jan 2015, he was admitted to the emergency department with reduced consciousness, with subsequent collapse and shock requiring endotracheal intubation. The patient died in Feb 2015. Adverse events near time of death were: brain oedema, cerebral haemorrhage, cerebral venous thrombosis, depressed level of consciousness, subdural haematoma and transverse sinus thrombosis.
